Instil Bio Inc TIL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TIL is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $10.61
- Day Range
- $10.56–10.90
- 52-Week Range
- $6.16–13.75
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $70.89 Mil
- Volume/Avg
- 6,217 / 14,262
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 49
- Website
- https://www.instilbio.com
Comparables
Valuation
|
Metric
|
TIL
|
CLDX
|
PRLD
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.31 | 4.87 | 0.87 |
Price/Sales | — | 263.40 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
TIL
CLDX
PRLD
Financial Strength
|
Metric
|
TIL
|
CLDX
|
PRLD
|
|---|---|---|---|
Quick Ratio | 14.24 | 13.69 | 10.67 |
Current Ratio | 15.22 | 13.87 | 10.79 |
Interest Coverage | −30.67 | — | — |
Quick Ratio
TIL
CLDX
PRLD
Profitability
|
Metric
|
TIL
|
CLDX
|
PRLD
|
|---|---|---|---|
Return on Assets (Normalized) | −16.61% | −30.49% | −38.93% |
Return on Equity (Normalized) | −23.03% | −33.19% | −43.41% |
Return on Invested Capital (Normalized) | −18.76% | −32.85% | −42.59% |
Return on Assets
TIL
CLDX
PRLD
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Gwxsrpmvt | Ctw | $578.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mzhdvpyl | Hrjnmz | $101.5 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Pxdfxxhl | Bspwv | $98.1 Bil | |
MRNA
| Moderna Inc | Wgvbssm | Rjb | $42.2 Bil | |
ARGX
| argenx SE ADR | Ckpzsrzq | Nrw | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Qkhflpqfx | Dhsy | $21.4 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Tqvbrwqsl | Bvmfcc | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Qfdtvyg | Qlcjmv | $15.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Jtcvshghp | Ptsqdy | $12.5 Bil | |
INCY
| Incyte Corp | Xqqvyjvc | Clykbtg | $11.7 Bil |